Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-valent HPV vaccine (B.E. Global)
- Development stage
- Preclinical
- Lead developer
- B.E. Global
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
The 9-valent HPV vaccine (B.E. Global) is a recombinant vaccine designed to prevent infections caused by nine types of human papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52, and 58. Developed through a partnership involving B.E. Global and BioNet-Asia, and manufactured by Global Biotech Products (GBP) in Thailand, the vaccine utilizes virus-like particles (VLPs) composed of the L1 capsid protein of each targeted HPV type. By inducing the production of neutralizing antibodies, the vaccine provides protection against HPV-related malignancies, including cervical, vulvar, vaginal, and anal cancers, as well as precancerous lesions and genital warts. This project is part of an initiative to establish local manufacturing capacity for high-valency vaccines in the Southeast Asian region.
- Other names
- 9-valent human papillomavirus vaccineGBP 9-valent HPV vaccineGBP9-valent HPV vaccineGBP-9-valent HPV vaccine
02
Targets
HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)HPV31 L1HPV33 L1HPV11 L1HPV18 L1HPV16 (Human papillomavirus type 16)HPV45 L1
Beyond the preview
Go deeper on 9-valent HPV vaccine (B.E. Global).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9-valent HPV vaccine (B.E. Global).